Abacus Global Management Stock Price, News & Analysis

Abacus Global Management (NASDAQ: ABL) reported strong Q1 2025 financial results, with total revenue more than doubling to $44.1 million compared to $21.5 million in Q1 2024. The company achieved GAAP net income of $4.6 million, reversing a $1.3 million loss from the previous year. Adjusted net income grew 158% to $17.3 million, while Adjusted EBITDA doubled to $24.5 million with a 55.6% margin.

Key highlights include $122.8 million in capital inflows to their Longevity Funds and origination capital deployment of $124.9 million. The company's policy portfolio expanded to 753 policies, up from 322 year-over-year. Abacus maintains its 2025 outlook for Adjusted net income between $70-78 million, projecting 51-68% growth compared to 2024.

Abacus Global Management (NASDAQ: ABL), a leader in alternative asset management, has scheduled its Q1 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call at 5:00 pm Eastern Time on the same day to discuss the results.

Investors can access the live webcast through the company's investor relations website at ir.abacusgm.com. For those preferring phone access, toll-free dial-in is available at (877) 407-9716, with international callers using (201) 493-6779. Participants are advised to dial in 10 minutes before the scheduled start time. A replay of the webcast will remain accessible on the company's IR website for one year following the call.

Abacus Global Management (NASDAQ: ABL) has highlighted its strong market position amid current volatility, according to CEO Jay Jackson. The company benefits from two key advantages: increased origination opportunities as clients seek alternative liquidity sources through life insurance policies, and growing investor interest in uncorrelated alternative assets for portfolio diversification.

The recent acquisition of Carlisle Management Company has enhanced Abacus' product lineup, with their GP/LP-style funds gaining significant traction among advisors. The company maintains a robust financial position with $128.8 million in cash and cash equivalents and $371.4 million in balance sheet policy assets as of December 31, 2024.

Abacus Global Management (NASDAQ: ABL) reported strong Q4 and full-year 2024 results, with notable growth across key metrics. Q4 total revenue increased 40% year-over-year to $33.2 million, while full-year revenue grew 69% to $111.9 million.

Q4 highlights include a 41% increase in origination capital deployment to $96.6 million and 214 policy originations. However, the company recorded a GAAP net loss of $18.3 million in Q4, primarily due to non-cash expenses related to stock compensation and acquisition costs.

Full-year 2024 saw policy originations grow 63% to 1,034, while adjusted EBITDA increased 57% to $61.6 million with a 55.0% margin. The company maintains a strong liquidity position with $128.8 million in cash and cash equivalents.

Looking ahead, Abacus projects 2025 adjusted net income between $70-78 million, representing 51-68% growth compared to 2024's $46.5 million.

Abacus Life (NASDAQ: ABL) has announced its rebranding to Abacus Global Management, reflecting its expanded global presence and comprehensive financial services. The company now operates through four key divisions:

• Abacus Life Solutions: Has purchased over $10B in life insurance policies since 2004, serving consumers and institutions
• Abacus Asset Group: Focuses on institutional investors, offering uncorrelated and longevity-based assets
• ABL Wealth: Provides data-driven wealth management using proprietary algorithms
• ABL Tech: Develops technology solutions for pension funds and insurance businesses

The rebranding will not affect existing client relationships or agreements, with enhanced offerings planned for the future.

Abacus Life (NASDAQ: ABL), a global alternative asset manager focused on longevity data and actuarial technology, has scheduled the release of its fourth quarter 2024 financial results on Thursday, March 27, 2025, after market close.

The company will host a conference call to discuss these financial results at 5:00 pm Eastern Time on the same day. Investors and interested parties can participate through:

• A live webcast available on Abacus' investor relations website at ir.abacuslife.com
• Dial-in numbers: (877) 407-9716 (toll-free) or (201) 493-6779 (international)

Participants are advised to dial in 10 minutes before the scheduled start time. A replay of the webcast will remain available on the company's investor relations website for one year following the call.

Abacus Life (NASDAQ: ABL) has entered into warrant exchange agreements with certain holders of its outstanding publicly traded warrants. The agreement involves the exchange of 4,930,745 Public Warrants for 1,134,071 shares of newly issued Common Stock, at a ratio of 0.23 shares per warrant.

The Public Warrants were originally issued during the company's IPO, allowing holders to purchase up to 17,250,000 shares of Common Stock at an exercise price of $11.50 per share. These warrants trade on Nasdaq under the symbol 'ABLLW' and are legally detachable and separately exercisable from the underlying common shares.

Abacus Life (NASDAQ: ABL) has completed the rebranding of FCF Advisors to Abacus FCF Advisors, a subsidiary of ABL Wealth. The company announced several key initiatives including:

- Launch of the Abacus FCF Small Cap Leaders ETF (ABLS)
- Management fee reductions of 5-10 basis points across all ETFs
- 18-month fee waiver of 20 basis points on four ETFs

The rebranding emphasizes the company's leadership in free cash flow investing and analytics through the FCF Leaders Model, which identifies the most profitable companies through a quantitative investment process. The company's ETF lineup now includes ABFL, ABLG, ABLD, ABOT, ABLS, and ABHY funds. To mark this milestone, the Abacus FCF Advisors team rang the Cboe Global Markets Exchange opening bell on February 19, 2025.

Coventry has released a new study by Professors Daniel Bauer and Nan Zhu revealing significant flaws in Lapetus Solutions' life expectancy estimates. The study analyzed 4,378 underwritten reports and found that Lapetus substantially understates actual life expectancies of insureds, which could significantly impact life settlement investors.

The research showed that while Lapetus's calculations predicted 648 policyholder deaths during the study period, only 203 actual deaths occurred, resulting in a concerning 31% ratio of actual to expected deaths. This aligns with a July 2024 analysis showing Lapetus life expectancies were shorter by approximately 31 months compared to other underwriters.

The findings suggest that policies valued using Lapetus's estimates could be overvalued, potentially affecting companies like Abacus (NASDAQ: ABL) that rely on their life expectancy predictions for policy valuations.